TY - JOUR
T1 - Suspected non-AD pathology in mild cognitive impairment
AU - Alzheimer's Disease Neuroimaging Initiative
AU - Wisse, Laura E.M.
AU - Butala, Nirali
AU - Das, Sandhitsu R.
AU - Davatzikos, Christos
AU - Dickerson, Bradford C.
AU - Vaishnavi, Sanjeev N.
AU - Yushkevich, Paul A.
AU - Wolk, David A.
N1 - Publisher Copyright:
© 2015 Elsevier Inc..
PY - 2015/12
Y1 - 2015/12
N2 - We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.
AB - We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.
KW - Amyloidosis
KW - Cerebrovascular disease
KW - Cognition
KW - Mild cognitive impairment
KW - Primary age-related tauopathy
KW - Suspected non-AD pathology
UR - http://www.scopus.com/inward/record.url?scp=84946562079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946562079&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2015.08.029
DO - 10.1016/j.neurobiolaging.2015.08.029
M3 - Article
C2 - 26422359
AN - SCOPUS:84946562079
SN - 0197-4580
VL - 36
SP - 3152
EP - 3162
JO - Neurobiology of aging
JF - Neurobiology of aging
IS - 12
ER -